Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin’s lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19)
- 9 August 2005
- journal article
- research article
- Published by Springer Science and Business Media LLC in Zeitschrift für Krebsforschung und Klinische Onkologie
- Vol. 132 (2), 105-112
- https://doi.org/10.1007/s00432-005-0023-2
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Bendamustine/Mitoxantrone/Rituximab (BMR): A Very Effective, Well Tolerated Outpatient Chemoimmunotherapy for Relapsed and Refractory CD20-positive Indolent Malignancies. Final Results of a Pilot StudyLeukemia & Lymphoma, 2004
- Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4), death-associated protein (Daxx) and with enforced caspase activationBiochemical Pharmacology, 2003
- High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomasZeitschrift für Krebsforschung und Klinische Onkologie, 2002
- Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkinʼs lymphomasAnti-Cancer Drugs, 2001
- Current approaches to the management of non-Hodgkin's lymphoma.1998
- Non-Hodgkin-LymphomeDer Internist, 1997
- Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell linesAnti-Cancer Drugs, 1996
- A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.1994
- Reporting outcomes in Hodgkin's disease and lymphoma.1987
- Advanced Lymphosarcoma: Intensive Cyclical Combination Chemotherapy with Cyclophosphamide, Vincristine, and PrednisoneAnnals of Internal Medicine, 1972